Clinical Trial Update: Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1 and Phase 2 results are reported for allogeneic cytokine-induced killer (CIK) cell immunotherapy given to patients who relapsed after allogeneic stem ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic cytokine-induced killer (CIK) cell therapy (cytokine-induced killer cells)

Snippet

Sponsor: Singapore General Hospital | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED